Preliminary outcomes of first-line treatment for metastatic colon cancer with mFOLFOXIRI combined with bevacizumab
Main Article Content
Abstract
Colon cancer is one of the most common malignancies and a leading cause of cancer-related mortality, particularly at the metastatic stage. This longitudinal descriptive study evaluated the efficacy of the mFOLFOXIRI regimen combined with bevacizumab in patients with unresectable metastatic colon treated at Hanoi Medical University Hospital between 2020 and 2024. Treatment outcomes were assessed by overall response rate (ORR), early tumor shrinkage (ETS), depth of response (DpR), and progression-free survival (PFS). Results: Fifty patients were included, of whom 72% were male, with a median age of 60.5 years old (range 25 – 76). All had an ECOG performance status of 0–1. Left-sided tumors accounted for 76%, liver metastases 74%, and RAS mutations were detected in 54% of patients. The median numbers of total treatment cycles and bevacizumab-containing cycles were 11.2 and 10.3, respectively. The ORR was 76%, ETS 62%, mDpR 48%, and mPFS 14.6 months. Conclusion: The mFOLFOXIRI plus bevacizumab regimen demonstrated high efficacy and prolonged progression-free survival in patients with unresectable metastatic colon cancer.
Article Details
Keywords
Metastatic colon cancer, mFOLFOXIRI, bevacizumab, early tumor shrinkage, depth of response, progression-free survival
References
2. Loupakis F, Cremolini C, Masi G, et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med. 2014;371(17):1609-1618. doi:10.1056/NEJMoa1403108
3. Cremolini C, Loupakis F, Antoniotti C, et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol. 2015;16(13):1306-1315. doi:10.1016/S1470-2045(15)00122-9
4. Satake H, Sunakawa Y, Miyamoto Y, et al. A phase II trial of 1st-line modified-FOLFOXIRI plus bevacizumab treatment for metastatic colorectal cancer harboring RAS mutation: JACCRO CC-11. Oncotarget. 2018;9(27):18811-18820. doi:10.18632/oncotarget.24702
5. Shen C, Hu H, Cai Y, et al. mFOLFOXIRI with or without bevacizumab for conversion therapy of RAS/BRAF/PIK3CA mutant unresectable colorectal liver metastases: the FORBES non-randomized phase II trial. Ann Transl Med. 2022;10(4):171. doi:10.21037/atm-21-6731
6. Huy TL, Hanh BM. Research on the treatment of metastatic colon cancer patients treated by FOLFOXIRI: Efficacy and toxicity of first-line treatment in stage IV metastatic colorectal cancer patients. Clin Investig. 2018;08(03). doi:10.4172/Clinical-Investigation.1000138
7. Heinemann V, von Weikersthal LF, Decker T, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014;15(10):1065-1075. doi:10.1016/S1470-2045(14)70330-4
8. Cremolini C, Antoniotti C, Stein A, et al. Individual Patient Data Meta-Analysis of FOLFOXIRI Plus Bevacizumab Versus Doublets Plus Bevacizumab as Initial Therapy of Unresectable Metastatic Colorectal Cancer. J Clin Oncol. 2020;38(28):3314-3324. doi:10.1200/JCO.20.01225
9. Cremolini C, Loupakis F, Lonardi S, et al. Early tumor shrinkage (ETS) and deepness of response (DoR) to predict progression-free, postprogression, and overall survival: Results from the phase III TRIBE trial. J Clin Oncol. 2014;32(3_suppl):521-521. doi:10.1200/jco.20 14.32.3_suppl.521